Design of MKC-442 (Emivirine) Analogues with Improved Activity Against Drug-Resistant HIV Mutants
- 9 October 1999
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 42 (22) , 4500-4505
Abstract
Two analogues of the nonnucleoside inhibitor of HIV-1 RT, MKC-442 (emivirine), containing different C6 substituents have been designed to be less susceptible to the commonly found drug-resistance mutation of Tyr181Cys. Compound TNK-6123 had a C6 thiocyclohexyl group designed to have more flexibility in adapting to the mutated drug-binding site. GCA-186 had additional 3‘,5‘-dimethyl substituents aimed at forming close contacts with the conserved residue Trp229. Both compounds showed ∼30-fold greater inhibitory effect than MKC-442 to the Tyr181Cys mutant virus as well as to the clinically important Lys103Asn virus. X-ray crystallographic structure determination of complexes with HIV-1 RT confirmed the predicted binding modes. These strategies might be used to improve the resilience of other NNRTI series against common drug-resistance mutations.Keywords
This publication has 17 references indexed in Scilit:
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998
- π-Stacking InteractionsJournal of Biological Chemistry, 1998
- The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection1Presented at the Eleventh International Conference on Antiviral Research, San Diego, CA, 5–10 April 1998.1Antiviral Research, 1998
- Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutionsJournal of Molecular Biology, 1997
- Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitorProceedings of the National Academy of Sciences, 1997
- Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside InhibitorsJournal of Medicinal Chemistry, 1996
- Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 å resolutionStructure, 1995
- Interactions Between Drug Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse TranscriptaseJournal of General Virology, 1994
- Crystal Structure at 3.5 Å Resolution of HIV-1 Reverse Transcriptase Complexed with an InhibitorScience, 1992
- Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.Proceedings of the National Academy of Sciences, 1991